Methods of treating hypertriglyceridemia
View Patent ↗In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising: administering orally to the subject about 4 capsules per day, each capsule comprising about 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters, by weight of all fatty acids present, for a period of at least about 12 weeks to effect a reduction in triglycerides without substantially increasing LDL-C compared to placebo control.
2. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.
3. The method of claim 1 , wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
4. The method of claim 1 , comprising administering to the subject said 4 capsules daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 10% without substantially increasing LDL-C compared to placebo control.
5. The method of claim 1 , comprising administering to the subject said 4 capsules daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 25% without substantially increasing LDL-C compared to placebo control.
6. The method of claim 1 , comprising administering to the subject said 4 capsules daily for the period of at least about 12 weeks to effect a reduction in apolipoprotein B compared to placebo control.
7. The method of claim 1 , comprising administering to the subject said 4 capsules daily for the period of at least about 12 weeks to effect a reduction in VLDL-C compared to placebo control.
8. The method of claim 1 wherein each capsule comprises about 925 mg of ethyl eicosapentaenoate.
9. The method of claim 1 wherein each capsule comprises about 950 mg of ethyl eicosapentaenoate.
10. The method of claim 1 wherein each capsule comprises about 975 mg of ethyl eicosapentaenoate.
11. The method of claim 1 wherein each capsule comprises about 1 g of ethyl eicosapentaenoate.